BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nath J, Paul R, Ghosh SK, Paul J, Singha B, Debnath N. Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects. Life Sciences 2020;258:118189. [DOI: 10.1016/j.lfs.2020.118189] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Laxmikeshav K, Himaja A, Shankaraiah N. Exploration of benzimidazoles as potential microtubule modulators: An insight in the synthetic and therapeutic evolution. Journal of Molecular Structure 2022;1253:132251. [DOI: 10.1016/j.molstruc.2021.132251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Choi HS, Ko YS, Jin H, Kang KM, Ha IB, Jeong H, Song HN, Kim HJ, Jeong BK. Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro. Molecules 2021;26:5118. [PMID: 34500557 DOI: 10.3390/molecules26175118] [Reference Citation Analysis]
3 Florio R, Carradori S, Veschi S, Brocco D, Di Genni T, Cirilli R, Casulli A, Cama A, De Lellis L. Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy. Pharmaceuticals (Basel) 2021;14:372. [PMID: 33920661 DOI: 10.3390/ph14040372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hsu M, Chen H, Chen C, Lien J, Gao J, Huang Y, Hsu JB, Lee GA, Huang S. Anti-Angiogenetic and Anti-Lymphangiogenic Effects of a Novel 2-Aminobenzimidazole Derivative, MFB. Front Oncol 2022;12:862326. [DOI: 10.3389/fonc.2022.862326] [Reference Citation Analysis]
5 Sun M, Zhang Y, Qin J, Ba M, Yao Y, Duan Y, Liu H, Yu D. Synthesis and biological evaluation of new 2-methoxyestradiol derivatives: Potent inhibitors of angiogenesis and tubulin polymerization. Bioorg Chem 2021;113:104988. [PMID: 34034135 DOI: 10.1016/j.bioorg.2021.104988] [Reference Citation Analysis]
6 Park D. Fenbendazole Suppresses Growth and Induces Apoptosis of Actively Growing H4IIE Hepatocellular Carcinoma Cells via p21-Mediated Cell-Cycle Arrest. Biol Pharm Bull 2022;45:184-93. [PMID: 35110505 DOI: 10.1248/bpb.b21-00697] [Reference Citation Analysis]
7 de Souza Gonçalves D, Yukuyama MN, Miyagi MYS, Silva TJV, Lameu C, Bou-chacra NA, de Araujo GLB. Revisiting Flubendazole Through Nanocrystal Technology: Statistical Design, Characterization and Its Potential Inhibitory Effect on Xenografted Lung Tumor Progression in Mice. J Clust Sci. [DOI: 10.1007/s10876-022-02220-x] [Reference Citation Analysis]
8 Peng Y, Pan J, Ou F, Wang W, Hu H, Chen L, Zeng S, Zeng K, Yu L. Fenbendazole and its synthetic analog interfere with HeLa cells’ proliferation and energy metabolism via inducing oxidative stress and modulating MEK3/6-p38-MAPK pathway. Chemico-Biological Interactions 2022;361:109983. [DOI: 10.1016/j.cbi.2022.109983] [Reference Citation Analysis]
9 Wang J, Sun D, Huang L, Wang S, Jin Y. Targeting Reactive Oxygen Species Capacity of Tumor Cells with Repurposed Drug as an Anticancer Therapy. Oxid Med Cell Longev 2021;2021:8532940. [PMID: 34539975 DOI: 10.1155/2021/8532940] [Reference Citation Analysis]
10 KalantarMotamedi Y, Ejeian F, Sabouhi F, Bahmani L, Nejati AS, Bhagwat AM, Ahadi AM, Tafreshi AP, Nasr-Esfahani MH, Bender A. Transcriptional drug repositioning and cheminformatics approach for differentiation therapy of leukaemia cells. Sci Rep 2021;11:12537. [PMID: 34131166 DOI: 10.1038/s41598-021-91629-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Liang D, Yu C, Ma Z, Yang X, Li Z, Dong X, Qin X, Du L, Li M. Identification of anthelmintic parbendazole as a therapeutic molecule for HNSCC through connectivity map-based drug repositioning. Acta Pharm Sin B 2022;12:2429-42. [PMID: 35646536 DOI: 10.1016/j.apsb.2021.12.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Huang L, Zhao L, Zhang J, He F, Wang H, Liu Q, Shi D, Ni N, Wagstaff W, Chen C, Reid RR, Haydon RC, Luu HH, Shen L, He TC, Tang L. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways. Aging (Albany NY) 2021;13:17407-27. [PMID: 34232919 DOI: 10.18632/aging.203232] [Reference Citation Analysis]
13 Jang J, Lee K, Koh B. Investigation of benzimidazole anthelmintics as oral anticancer agents. Bulletin Korean Chem Soc. [DOI: 10.1002/bkcs.12519] [Reference Citation Analysis]
14 Montecinos F, Loew M, Chio TI, Bane SL, Sackett DL. Interaction of Colchicine-Site Ligands With the Blood Cell-Specific Isotype of β-Tubulin—Notable Affinity for Benzimidazoles. Front Cell Dev Biol 2022;10:884287. [DOI: 10.3389/fcell.2022.884287] [Reference Citation Analysis]
15 Costa A, Vale N. Strategies for the treatment of breast cancer: from classical drugs to mathematical models. Math Biosci Eng 2021;18:6328-85. [PMID: 34517536 DOI: 10.3934/mbe.2021316] [Reference Citation Analysis]
16 Huang M, Wang C, Yao Y, Li H, Yao Y, Zhu Y, Cui Y, Yuan Y, Sha J. Mebendazole-Induced Blood-Testis Barrier Injury in Mice Testes by Disrupting Microtubules in Addition to Triggering Programmed Cell Death. Int J Mol Sci 2022;23:4220. [PMID: 35457043 DOI: 10.3390/ijms23084220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Esfahani MKM, Islam N, Cabot PJ, Izake EL. Development of Thiabendazole-Loaded Mesoporous Silica Nanoparticles for Cancer Therapy. ACS Biomater Sci Eng 2021. [PMID: 34056895 DOI: 10.1021/acsbiomaterials.1c00066] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]